Theragenics Signs Brachytherapy Supply, Reseller Deal with Accelyon

Theragenics Corporation^®

, a medical device company serving the surgical products and prostate cancer treatment markets, today announced it has signed a Supply and Reseller agreement with Accelyon Limited. Under the three-year agreement, Theragenics will supply its AgX100^® seeds to Accelyon who will provide for the loading and packaging of the seeds into prescription loaded needles, custom strands and other configurations. Accelyon will distribute the finished products in the European Union, Australia and New Zealand. “This Agreement is our first major opportunity to penetrate Europe, Australia and New Zealand with our brachytherapy seed product,” said M. Christine Jacobs, Chairman and Chief Executive Officer of Theragenics Corporation. “Accelyon is a new entrant into the brachytherapy marketplace with experienced talent. The company is managed by industry veterans possessing direct brachytherapy experience in all these markets. We have expected our AgX100^® iodine seed to provide opportunities outside of the United States. Accelyon provides us this access in these important brachytherapy markets. They have international expertise and reach we do not possess. We are thrilled to begin a new brachytherapy relationship with Accelyon.” “Accelyon's people bring a wealth of experience in the European and Australasia brachytherapy marketplaces,” said Saheed Rashid, Managing Director of Accelyon. “We understand what is important to customers and are committed to delivering the highest standards of quality and reliability. Theragenics is a high quality manufacturer and well-known brand throughout the brachytherapy world. They share Accelyon's commitment to this important treatment. We are excited to begin this new relationship with Theragenics.”